LG Chem 
Welcome,         Profile    Billing    Logout  
 40 Products   109 Diseases   40 Products   37 Trials   1902 News 


«12...4567891011121314...1920»
  • ||||||||||  Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
    Trial completion, Trial completion date, Combination therapy:  INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) -  Mar 30, 2021   
    P=N/A,  N=70, Completed, 
    In conclusion, polynucleotide sodium could effectively reduce weight-bearing pain in the patients with knee osteoarthritis compared to standard hyaluronic acid viscosupplementation. Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Mar 2021
  • ||||||||||  Xospata (gilteritinib) / Astellas, Fotivda (tivozanib) / AVEO, Jazz
    [VIRTUAL] Cytoplasmic Expression of XPO7 Distinguishes a Subset of Ovarian Carcinoma Vulnerable to SLK Inhibition () -  Mar 26, 2021 - Abstract #SSO2021SSO_102;    
    Treatment of XPO7:SLK expressing human and mouse OC cell lines with two kinase inhibitors with activity against SLK – tivozanib and gilteritinib – abrogated tumorsphere formation in vitro. We have identified XPO7 as a biomarker for aggressive disease in OC and provide evidence for therapeutic targeting of SLK with small molecule kinase inhibitors in XPO7 expressing tumors.
  • ||||||||||  Follitrope (recombinant human follicle stimulating hormone) / LG Chem
    Review, Enrollment change, Trial completion date, Trial primary completion date:  MSP-IVC: Minimal Stimulation Protocol Using Aromek(Letrozole) and Follitrope(recFSH) Combined With INVOCell-Low Cost IVF (clinicaltrials.gov) -  Mar 24, 2021   
    P=N/A,  N=30, Recruiting, 
    We have identified XPO7 as a biomarker for aggressive disease in OC and provide evidence for therapeutic targeting of SLK with small molecule kinase inhibitors in XPO7 expressing tumors. N=100 --> 30 | Trial completion date: Feb 2012 --> Mar 2022 | Trial primary completion date: Dec 2011 --> Dec 2021
  • ||||||||||  Avastin (bevacizumab) / Roche
    Review, Journal:  A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer. (Pubmed Central) -  Mar 23, 2021   
    In this review, we have assessed studies focused upon the treatment of non-small cell lung cancer. Some therapies are approved, such as bevacizumab and atezolizumab, while some are still in clinical trials, such as ficlatuzumab and ipilimumab, and others have been rejected due to inadequate disease control, such as figitumumab.
  • ||||||||||  Adalimumab BS MA (adalimumab biosimilar) / Mochida, LG Chem
    Trial completion:  A Study Comparing LBAL to Humira (clinicaltrials.gov) -  Mar 15, 2021   
    P3,  N=383, Completed, 
    The larger and longer follow-up will be essential to determine these beneficial effects. Active, not recruiting --> Completed
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    [VIRTUAL] Tyrosine kinome profiling of renal cell carcinoma (RCC) () -  Mar 11, 2021 - Abstract #AACR2021AACR_1510;    
    Furthermore, we have demonstrated different inhibitory effects of TKIs ex-vivo and identified two peptide clusters significantly affected by TKI. Further analysis of affected kinases and signaling pathways as well as correlations with clinical data for the same group of patients will be performed.